|Description||Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals for the treatment of ulcerative colitis and Crohn's disease under the trade name Entyvio. Vedolizumab binds to integrin α4β7 (LPAM-1) and blocks α4β7, displaying anti-inflammatory activity.|
|Application||the treatment of ulcerative colitis and Crohn's disease|
|Current Developer||Millennium Pharmaceuticals|
Firategrast is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous syste...
β-[[[4,5-Dihydro-5-[2-(1H-imidazol-2-ylamino)ethyl]-3-isoxazolyl]carbonyl]amino]-3,4-dihydro-γ-oxo-2(1H)-Isoquinolinebutanoic Acid is a de...
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor which can be used to modify the surface of cardiovascular implants such as vascular grafts to p...
CWHM 12 demonstrated high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assay...
Cilengitide is a cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and ...
ATN-161 is a small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for i...
BIO 5192 is a selective and potent inhibitor of integrin α4β1 (Very Late Antigen-4; VLA-4) (Kd < 10 pM) wth selectivity for α4β1 over a range of other integrins...
Cilengitide TFA salt
Cilengitide TFA salt, is a cyclic Arg-Gly-Asp acid pentapeptide that induces anoikis in angiogenic blood vessels and brain tumor, selectively and potently block...